(Q38221463)

31 August 2017

title

Emerging strategies to overcome resistance to endocrine therapy for breast cancer (English)

1 reference

31 August 2017

M Firdos Ziauddin

1

1 reference

31 August 2017

Dong Hua

series ordinal

2

1 reference

31 August 2017

Shou-Ching Tang

series ordinal

3

1 reference

31 August 2017

publication date

1 September 2014

1 reference

Cancer and Metastasis Reviews

31 August 2017

published in

1 reference

31 August 2017

volume

33

1 reference

31 August 2017

issue

2-3

1 reference

31 August 2017

page(s)

791-807

1 reference

https://scigraph.springernature.com/pub.10.1007/s10555-014-9504-6

31 August 2017

exact match

0 references

cites work

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Incidence of breast cancer in the United States: current and future trends.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Estrogen receptors: therapies targeted to receptor subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

The different roles of ER subtypes in cancer biology and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Estrogen receptor interaction with co-activators and co-repressors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Estrogen receptors: how do they signal and what are their targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Estrogen action and cytoplasmic signaling pathways. Part II: the role of growth factors and phosphorylation in estrogen signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Estrogen action and cytoplasmic signaling cascades. Part I: membrane-associated signaling complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Estrogen receptors outside the nucleus in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

A transmembrane intracellular estrogen receptor mediates rapid cell signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Growth factor stimulation induces a distinct ER(alpha) cistrome underlying breast cancer endocrine resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Palbociclib (PD 0332991) : targeting the cell cycle machinery in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Estradiol receptors in breast cancer cells: associated co-factors as targets for new therapeutic approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

The best use of adjuvant endocrine treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Her2 and progesterone receptor status are not predictive of response to fulvestrant treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Co-targeting estrogen receptor and HER2 pathways in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

ErbB receptor signaling and therapeutic resistance to aromatase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

21 January 2018

A renaissance for SRC

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Crosstalk between steroid receptors and the c-Src-receptor tyrosine kinase pathways: implications for cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Elevated Src kinase activity attenuates Tamoxifen response in vitro and is associated with poor prognosis clinically

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

New and emerging HDAC inhibitors for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Histone deacetylase inhibitor induced modulation of anti-estrogen therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Histone deacetylase inhibition and estrogen signalling in human breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Inhibition of histone deacetylase enhances the anti-proliferative action of antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal a

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Efficacy of histone deacetylase and estrogen receptor inhibition in breast cancer cells due to concerted down regulation of Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Increased survival with enzalutamide in prostate cancer after chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Endoxifen's molecular mechanisms of action are concentration dependent and different than that of other anti-estrogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Coprescription of tamoxifen and medications that inhibit CYP2D6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

BAG-1, an anti-apoptotic tumour marker

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

BAG-1 expression correlates with Bcl-2, p53, differentiation, estrogen and progesterone receptors in invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

The nuclear BAG-1 isoform, BAG-1L, enhances oestrogen-dependent transcription.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Modulation of BAG-1 expression alters the sensitivity of breast cancer cells to tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Activating ESR1 mutations in hormone-resistant metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Inhibiting HSP90 to treat cancer: a strategy in evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

AGR2 predicts tamoxifen resistance in postmenopausal breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

Anterior gradient-2 plays a critical role in breast cancer cell growth and survival by modulating cyclin D1, estrogen receptor-alpha and survivin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

CXCR4 activation maintains a stem cell population in tamoxifen-resistant breast cancer cells through AhR signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

AIB1:ERα transcriptional activity is selectively enhanced in aromatase inhibitor-resistant breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

S6K1 inhibition enhances tamoxifen-induced cell death in MCF-7 cells through translational inhibition of Mcl-1 and survivin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-014-9504-6

10.1007/S10555-014-9504-6

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

31 August 2017

1007327196

0 references

1 reference